Alpha Laboratories Ltd. Introduces a range of Polyethylene glycol allergens from BÜHLMANN to the UK. Designed for use with the FlowCAST basophil activation assay, the allergens provide a safer approach to determine those with a hypersensitivity reaction to PEG.
Allergy to Polyethylene glycol (PEG) is rare but can be severe, and is suspected to be the primary cause of adverse reactions to COVID-19 vaccines. PEG is used as a stabiliser of lipid nanoparticles in the formulation of mRNA-based vaccines, thus allergy to it is increasingly being recognised.
Basophil activation testing (BAT) has been validated to support and investigate Polyethylene glycol (PEG) hypersensitivity reactions. Performed on whole blood samples, it offers a safer, non-invasive alternative to allergy testing, compared with traditional in-vivo allergy tests, such as a skin prick test
As PEGs at different molecular weights may result in different reactivity of patient basophils, BÜHLMANN has produced multiple PEG allergens to maximise the chance of detecting an allergic response in a patient:
PEG 4000 - Linear PEG of molecular weight in the range of 3500-4500
PEG 2000 - Linear PEG of molecular weight in the range of 1900-2200
DMG PEG 2000 - Lipid component with a PEG 2000 chain